[Dipeptidyl peptidase-4 inhibitors as treatment for diabetes mellitus]

Tapia López E, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A
Record ID 32018001386
Authors' recomendations: CONCLUSIONS High quality evidence shows that in patients with type 2 diabetes mellitus, first-line therapy with dipeptidyl peptidase-4 inhibitors plus metformin is associated to a slight reduction in glycosylated hemoglobin, fasting plasma glucose and weight; however, its use as monotherapy does not have any benefit. As second-line therapy, its combination with metformin is associated to weight loss and fewer hypoglycemia events; also, low quality evidence associates it with low risk of cardiovascular events when compared with metformin plus sulfonylureas. As third-line therapy, its use added to insulin was associated to a significant reduction in glycosylated hemoglobin and plasma glucose. As regards safety, the use of saxagliptin is associated to a higher risk of experiencing heart failure. The clinical practice guidelines identified suggest them as a therapeutic alternative as first-line (when there intolerance or metformin is contraindicated); they also suggest its use in combination with metformin (as well as other alternatives) as second-line therapy when the first-line clinical goal has not been achieved.
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Diabetes Mellitus, Type 2
  • Drug Therapy
  • Dipeptidyl-Peptidase IV Inhibitors
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.